<DOC>
	<DOCNO>NCT01794975</DOCNO>
	<brief_summary>The primary objective study investigate whether striatal [ 11C ] ORM-13070 uptake reduce physiological pharmacological challenge increase synaptic concentration noradrenaline human brain . Each subject undergo 3 PET scan , baseline PET scan two scan noradrenaline challenge : intravenous administration ketamine oral administration atomoxetine combine cold pressor test subject 's foot place 8 Â°C water basin . Eight healthy male subject include study .</brief_summary>
	<brief_title>Changes Striatal 11CORM-13070 Binding Elicited Changing Levels Endogenous Noradrenaline</brief_title>
	<detailed_description>Objectives The primary objective study investigate whether striatal [ 11C ] ORM-13070 uptake reduce physiological pharmacological challenge increase synaptic concentration endogenous alpha2C-adrenoceptor agonist , noradrenaline , human brain . Methodology PET use study effect two different noradrenaline challenge striatal uptake novel alpha2C-adrenoceptor imaging agent , [ 11C ] ORM-13070 . Each eight study subject undergo one baseline PET scan without pretreatment two scan two different noradrenaline challenge : i.v . infusion ketamine single oral dose atomoxetine combine cold pressor test . The sequence baseline scan scan subject base balanced randomization . Double-blind administration pretreatments possible , PET scan data analyze person aware treatment identity . Venous blood sample collect determination concentration [ 11C ] ORM-13070 tracer radioactive metabolite , test drug atomoxetine ketamine , endogenous noradrenaline biomarker employ challenge . Blood pressure heart rate measure physiological indicator sympathetic activation . Subject safety monitor vital sign , question clinical observation . The bind potential tracer striatum baseline compare tracer bind potential noradrenaline challenge . Sample size Eight healthy male subject include study . Discontinued subject may replace new subject decide Principal Investigator Duration treatment After screen visit , interval 45 day first PET visit . Each subject undergo 3 PET scan : baseline PET scan , two scan noradrenaline challenge . The PET experiment subject separated interval least 5 day . An end-of-study visit take place within 21 day last PET scan . Assessments Efficacy : Alpha2C-adrenoceptor occupancy caudate nucleus putamen assess use PET image agent [ 11C ] ORM-13070 administration two noradrenaline challenge , ketamine atomoxetine combine cold pressor test . Differences striatal receptor occupancy tracer assess use establish reference tissue model bind potential non-displaceable compartment ( BPND ) accord equation : Occupancy = [ ( BPND bl - BPND challenge ) / BPNDbl x 100 % ] . Plasma noradrenaline concentration measure biochemical biomarker intervention validate employ noradrenaline challenge . Blood pressure heart rate use physiological biomarkers . Safety : Vital sign , subjective symptom ECG monitor PET visit . Subjects remain study center minimum 4 h PET scan , subject discharge base clinical evaluation safety check list . Pharmacokinetics : Venous blood sample collect determination concentration [ 11C ] ORM-13070 tracer radioactive metabolite , pretreatment agent atomoxetine ketamine pre-defined time point order provide information fraction intact tracer blood document exposure pharmacological agent PET scan . No formal pharmacokinetic calculation perform . Statistical method : Efficacy , safety pharmacokinetics : Differences striatal [ 11C ] ORM-13070 uptake baseline condition different pretreatments consider primary outcome variable statistical analysis carry analysis variance . Descriptive statistical analysis tracer fraction blood scan concentration employ pretreatment agent carry . Demographic baseline data , laboratory safety determination , physical examination , BP , HR , ECG , AEs concomitant treatment summarise descriptive statistic list .</detailed_description>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<criteria>1 . Written informed consent ( IC ) obtain . 2 . Good general health ascertain detailed medical history , laboratory investigation physical examination . 3 . Males 20 40 year age ( inclusive ) . 4 . Body mass index ( BMI ) 1828 kg/m2 ( inclusive ) . 5 . Weight 60100 kg ( inclusive ) . 1 . Suspected poor compliance protocol inability communicate well study personnel . 2 . Veins unsuitable repeated venipuncture . 3 . CYP2D6 slow metabolizer ultrarapid metabolizer genotype . 4 . Evidence clinically significant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolicendocrine , neurological , urogenital psychiatric disease judge investigator . 5 . Any condition require regular concomitant medication include herbal product likely need concomitant medication study . 6 . Susceptibility severe allergic reaction . 7 . Intake medication could affect outcome study , within 2 week prior tracer administration ( 2 month enzyme induce drug like rifampicin carbamazepine ) , less 5 time halflife medication . 8 . Regular consumption 21 unit alcohol per week ( 1 unit = 4 cl spirit , 13 g alcohol ) . 9 . Current use nicotinecontaining product 5 cigarette equivalent/day . 10 . Inability refrain use nicotinecontaining product stay study centre . 11 . Inability refrain consume caffeinecontaining beverage stay study centre , e.g . propensity headache refrain caffeinecontaining beverage . 12 . Blood donation loss significant amount blood within 2 month prior screen visit . 13 . Abnormal 12lead electrocardiogram ( ECG ) find clinical relevance 10 minute rest supine position screen visit 14 . Heart rate ( HR ) &lt; 40 beats/minute &gt; 90 beats/minute 10 minute rest supine position screen visit . 15 . At screen visit , systolic blood pressure ( BP ) &lt; 90 mmHg &gt; 140 mmHg 10 minute supine position , diastolic BP &lt; 50 mmHg &gt; 90 mmHg 10 minute supine position . 16 . Any abnormal laboratory value , vital sign physical examination result , may opinion investigator interfere interpretation test result cause health risk subject take part study . 17 . History drug abuse positive result drug abuse test . 18 . Positive serology human immunodeficiency virus antibody ( HIVAb ) , hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCVAb ) . 19 . Anatomical abnormality brain MRI may opinion investigator interfere interpretation PET result . 20 . Any condition opinion investigator would interfere evaluation result constitute health risk subject . 21 . Participation another clinical drug study within 3 month prior study . 22 . Participation prior PET study medical occupational exposure significant dose ionize radiation . 23 . Any contraindication MRI brain .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>PET</keyword>
	<keyword>striatum</keyword>
	<keyword>receptor occupancy</keyword>
	<keyword>noradrenaline</keyword>
	<keyword>alpha2c</keyword>
</DOC>